We are live on ! Find out more
Pacer Advisors

Pacer Advisors Portfolio holdings

AUM $35.6B
1-Year Est. Return 18.19%
This Fund
S&P 500
This Quarter Est. Return
-4.36%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$44.1B
AUM Growth
+$629M
Cap. Flow
+$2.39B
Cap. Flow %
5.42%
Top 10 Hldgs %
11.51%
Holding
3,945
New
199
Increased
895
Reduced
1,260
Closed
190

Top Sells

Rank Stock Value
1
VST icon
Vistra
VST
+$598M
2
XOM icon
ExxonMobil
XOM
+$504M
3
CVX icon
Chevron
CVX
+$443M
4
OXY icon
Occidental Petroleum
OXY
+$439M
5
CMI icon
Cummins
CMI
+$414M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 17.1%
2 Technology 16.69%
3 Energy 13.9%
4 Industrials 11.2%
5 Healthcare 9.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ATKR icon
1251
Atkore
ATKR
$2.54B
$63.1K ﹤0.01%
468
-131
-22% -$20.9K
TU icon
1252
Telus
TU
$16.2B
$62.8K ﹤0.01%
4,147
-200
-5% -$3.22K
FIZZ icon
1253
National Beverage
FIZZ
$2.93B
$61.1K ﹤0.01%
1,192
+65
+6% +$3.04K
SMPL icon
1254
Simply Good Foods
SMPL
$943M
$60.2K ﹤0.01%
1,665
+215
+15% +$7.68K
LNN icon
1255
Lindsay Corp
LNN
$1.17B
$59K ﹤0.01%
480
-353,579
-100% -$41.2M
WIRE
1256
DELISTED
Encore Wire Corp
WIRE
$58.5K ﹤0.01%
202
-461,399
-100% -$130M
PRGS icon
1257
Progress Software
PRGS
$1.59B
$58.5K ﹤0.01%
1,078
+399
+59% +$20.2K
BPMC
1258
DELISTED
Blueprint Medicines
BPMC
$58.2K ﹤0.01%
540
+77
+17% +$7.71K
MDGL icon
1259
Madrigal Pharmaceuticals
MDGL
$12.7B
$58K ﹤0.01%
207
+37
+22% +$8.81K
RAMP icon
1260
LiveRamp
RAMP
$2.3B
$56.9K ﹤0.01%
1,838
-150
-8% -$4.82K
CRSP icon
1261
CRISPR Therapeutics
CRSP
$4.6B
$56.1K ﹤0.01%
1,038
+500
+93% +$28.9K
ACLS icon
1262
Axcelis
ACLS
$3.94B
$52.9K ﹤0.01%
372
+163
+78% +$18.8K
APLS
1263
DELISTED
Apellis Pharmaceuticals
APLS
$52.8K ﹤0.01%
1,376
+684
+99% +$31K
TR icon
1264
Tootsie Roll Industries
TR
$2.9B
$52.3K ﹤0.01%
+1,814
New +$51.2K
WDFC icon
1265
WD-40
WDFC
$3.13B
$51.4K ﹤0.01%
234
-215
-48% -$49.7K
ROG icon
1266
Rogers Corp
ROG
$2.31B
$51.1K ﹤0.01%
+424
New +$49.7K
DIN icon
1267
Dine Brands
DIN
$448M
$48.6K ﹤0.01%
1,343
+600
+81% +$24.9K
IONS icon
1268
Ionis Pharmaceuticals
IONS
$9.25B
$45.8K ﹤0.01%
960
-11
-1% -$451
BL icon
1269
BlackLine
BL
$1.8B
$45.2K ﹤0.01%
932
+286
+44% +$15.7K
SNAP icon
1270
Snap
SNAP
$7.6B
$44.6K ﹤0.01%
2,683
-2,675
-50% -$38.4K
KRYS icon
1271
Krystal Biotech
KRYS
$10.4B
$43.7K ﹤0.01%
238
-14
-6% -$2.35K
INSM icon
1272
Insmed
INSM
$22.7B
$42.7K ﹤0.01%
638
-898
-58% -$34.8K
CERE
1273
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$42.6K ﹤0.01%
1,043
+8
+0.8% +$333
RVMD icon
1274
Revolution Medicines
RVMD
$40B
$41K ﹤0.01%
1,056
-270
-20% -$10.1K
PCVX icon
1275
Vaxcyte
PCVX
$8.01B
$40.7K ﹤0.01%
539
-50
-8% -$3.4K

Similar funds

Pacer Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Pacer Advisors held 3,945 positions worth $44.1B, up 1.4% from $43.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Pacer Advisors deployed $2.39B of net new capital in Q2 2024, opening 199 new positions and adding to 895 existing holdings. Its largest new stake was Academy Sports + Outdoors: 3,268,629 shares worth $174M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 17% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Vistra, an estimated $598M trimmed.

  • Pacer Advisors's largest Q2 2024 buy was Academy Sports + Outdoors: 3,268,629 shares worth $174M.
  • Pacer Advisors added most to Halliburton in Q2 2024, an estimated $500M increase.
  • Pacer Advisors's biggest Q2 2024 reduction was Vistra, cutting an estimated $598M.
  • Pacer Advisors fully exited American Eagle Outfitters in Q2 2024, selling an estimated $218M.
  • Pacer Advisors's ten largest holdings make up 12% of its $44.1B portfolio in Q2 2024.
  • Pacer Advisors opened 199 new positions and closed 190 in Q2 2024.
  • Pacer Advisors's portfolio value rose 1.4% quarter-over-quarter to $44.1B.

Based on Pacer Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.